{"protocolSection": {"identificationModule": {"nctId": "NCT00419757", "orgStudyIdInfo": {"id": "D5896C00021"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "An Efficacy Study Comparing SYMBICORT\u00ae Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma", "officialTitle": "A 12-week, Randomised, Double Blind, Active-controlled, Multi-centre, Phase IIIB Study Comparing the Efficacy and Safety of SYMBICORT\u00ae pMDI 160/4.5 mg x 2 Actuations Twice Daily Versus Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily, in Adult/Adolescent (> 12 Yrs) Hispanic Subjects With Asthma"}, "statusModule": {"statusVerifiedDate": "2012-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-01"}, "primaryCompletionDateStruct": {"date": "2008-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-01-05", "studyFirstSubmitQcDate": "2007-01-05", "studyFirstPostDateStruct": {"date": "2007-01-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-05-20", "resultsFirstSubmitQcDate": "2012-08-24", "resultsFirstPostDateStruct": {"date": "2012-08-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-08-24", "lastUpdatePostDateStruct": {"date": "2012-08-27", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine the effectiveness and safety of SYMBICORT\u00ae pMDI (a medication approved by the Food and Drug Administration(FDA)) in the Hispanic population."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Moderate asthma", "Severe asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 558, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Symbicort", "type": "ACTIVE_COMPARATOR", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2 actuations twice daily", "interventionNames": ["Drug: Budesonide/formoterol (SYMBICORT) pMDI"]}, {"label": "Budesonide", "type": "ACTIVE_COMPARATOR", "description": "budesonide HFA pMDI 160 \u03bcg x 2 actuations twice daily", "interventionNames": ["Drug: Budesonide HFA pMDI"]}], "interventions": [{"type": "DRUG", "name": "Budesonide/formoterol (SYMBICORT) pMDI", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2 actuations twice daily", "armGroupLabels": ["Symbicort"]}, {"type": "DRUG", "name": "Budesonide HFA pMDI", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily", "armGroupLabels": ["Budesonide"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Morning Peak Expiratory Flow (AM PEF)", "description": "Change from baseline (average of daily records over the 14 days of run-in) to the average of daily records over the treatment period of 12 weeks, with baseline value as covariate.", "timeFrame": "Baseline (run-in) and throughout 12 weeks"}], "secondaryOutcomes": [{"measure": "Percentage of Participants With Pre-defined Asthma Events", "description": "Asthma Events, defined as any of: decrease in lung function (FEV1 or AM PEF), use of rescue medication over maximum allowed per day, night awakening requiring use of rescue medication, exacerbation of asthma requiring medical assistance, use of not allowed asthma medication", "timeFrame": "12 weeks"}, {"measure": "Percentage of Participants With \"Withdrawals Due to Pre-defined Asthma Events\"", "description": "Percentage of participants with \"Withdrawals Due to Pre-defined Asthma Events\" as recorded in CRF. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "timeFrame": "12 weeks"}, {"measure": "Changes Pre-dose Forced Expiratory Volume in 1 Second (FEV1)", "description": "Changes in pre-dose FEV1 from baseline to the average value over the treatment period, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "timeFrame": "Baseline, 2, 6 and 12 weeks"}, {"measure": "Change From Baseline in a Evening Peak Expiratory Flow (PM PEF)", "description": "Change from baseline (average of daily records over the 14 days of run-in) to the average of daily records over the treatment period of 12 weeks with baseline as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "timeFrame": "Baseline (run-in) and throughout 12 weeks"}, {"measure": "Change in Nighttime Asthma Symptom Score From Baseline Through 12 Weeks", "description": "Change from baseline in average of daily scores for nighttime asthma over 12 weeks of treatment, with baseline value as covariate.\n\nDaily scale:\n\n* 0 = No symptoms\n* 1 = Mild symptoms\n* 2 = Moderate symptoms\n* 3 = Severe symptoms", "timeFrame": "Baseline (run-in) and throughout 12 weeks"}, {"measure": "Change in Daytime Asthma Symptom Score From Baseline Through 12 Weeks", "description": "Change from baseline in average of daily scores for daytime asthma over 12 weeks of treatment, with baseline value as covariate.\n\nDaily scale:\n\n* 0 = No symptoms\n* 1 = Mild symptoms\n* 2 = Moderate symptoms\n* 3 = Severe symptoms", "timeFrame": "Baseline (run-in) and throughout 12 weeks"}, {"measure": "Change in Asthma Related Awakenings Free Nights, From Baseline Through 12 Weeks", "description": "Change from baseline in percentage of nights with awakenings due to asthma over 12 weeks of treatment, with baseline value as covariate.", "timeFrame": "Baseline (run-in) and throughout 12 weeks"}, {"measure": "Change From Baseline in Rescue Medication Use Over 12 Weeks of Treatment", "description": "Change from baseline in rescue medication use over 12 weeks of treatment with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "timeFrame": "Baseline (run-in) and throughout 12 weeks"}, {"measure": "Change From Baseline in Rescue-free Days Over 12 Weeks of Treatment", "description": "Change from baseline in percentage of rescue-free days over 12 weeks of treatment, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "timeFrame": "Baseline (run-in) and throughout 12 weeks"}, {"measure": "Change From Baseline in Symptom-free Days Over 12 Weeks of Treatment", "description": "Change from baseline in percentage of symptom-free days over 12 weeks of treatment, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "timeFrame": "Baseline (run-in) and throughout 12 weeks"}, {"measure": "Subject Global Assessment", "description": "The assessment was made using a 5-point Likert scale with 1=much better, 2=somewhat better, 3=comparable, 4=somewhat worse, and 5=much worse transformed to a binary variable with points 1 and 2 combined as \"Yes\" and points 3, 4, 5 as \"No\". Percent of Participants that gave positive responses.", "timeFrame": "Baseline and week 12"}, {"measure": "Physician Global Assessment", "description": "The assessment was made using a 5-point scale with 1=much better, 2=somewhat better, 3=comparable, 4=somewhat worse, and 5=much worse transformed to a binary variable with points 1and 2 combined as \"Yes\" and points 3, 4, 5 as \"No\". Percent of Participants that gave positive responses.", "timeFrame": "Baseline and week 12"}, {"measure": "Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Control Relief Index", "description": "Mean scores (6-points scale, where 1-means the most positive opinion and 6-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0\u00b1100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.", "timeFrame": "Week 12"}, {"measure": "Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Overall Perception of Medication", "description": "Mean scores (6 or 5-points scale, where 1-means the most positive opinion and 5/6-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0\u00b1100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.", "timeFrame": "Week 12"}, {"measure": "Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Comparison With Other Medications", "description": "Mean scores (5-points scale, where 1-means the most positive opinion and 5-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0\u00b1100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.", "timeFrame": "Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or Female, Hispanic (self-reported), \\> 12 years of age\n* Moderate to severe asthma requiring treatment with an inhaled corticosteroid\n* Diagnosis of asthma for at least 6 months\n\nExclusion Criteria:\n\n* Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)\n* Any significant disease or disorder that may jeopardize a subject's safety", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Christer Hultquist, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Anaheim", "state": "California", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Research Site", "city": "Chula Vista", "state": "California", "country": "United States", "geoPoint": {"lat": 32.64005, "lon": -117.0842}}, {"facility": "Research Site", "city": "Fresno", "state": "California", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Research Site", "city": "Fullerton", "state": "California", "country": "United States", "geoPoint": {"lat": 33.87029, "lon": -117.92534}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "National City", "state": "California", "country": "United States", "geoPoint": {"lat": 32.67811, "lon": -117.0992}}, {"facility": "Research Site", "city": "Rancho Cordova", "state": "California", "country": "United States", "geoPoint": {"lat": 38.58907, "lon": -121.30273}}, {"facility": "Research Site", "city": "Rancho Mirage", "state": "California", "country": "United States", "geoPoint": {"lat": 33.73974, "lon": -116.41279}}, {"facility": "Research Site", "city": "Riverside", "state": "California", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Research Site", "city": "Sacramento", "state": "California", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Research Site", "city": "San Diego", "state": "California", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Research Site", "city": "San Francisco", "state": "California", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"facility": "Research Site", "city": "Stockton", "state": "California", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Research Site", "city": "Torrance", "state": "California", "country": "United States", "geoPoint": {"lat": 33.83585, "lon": -118.34063}}, {"facility": "Research Site", "city": "Pueblo", "state": "Colorado", "country": "United States", "geoPoint": {"lat": 38.25445, "lon": -104.60914}}, {"facility": "Research Site", "city": "Largo", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.90979, "lon": -82.78842}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Naranja", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.51816, "lon": -80.42283}}, {"facility": "Research Site", "city": "North Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.89009, "lon": -80.18671}}, {"facility": "Research Site", "city": "Orlando", "state": "Florida", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Research Site", "city": "Panama City", "state": "Florida", "country": "United States", "geoPoint": {"lat": 30.15946, "lon": -85.65983}}, {"facility": "Research Site", "city": "South Miami", "state": "Florida", "country": "United States", "geoPoint": {"lat": 25.7076, "lon": -80.29338}}, {"facility": "Research Site", "city": "Chicago", "state": "Illinois", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Research Site", "city": "Newburgh", "state": "New York", "country": "United States", "geoPoint": {"lat": 41.50343, "lon": -74.01042}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Philadelphia", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Research Site", "city": "Boerne", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Research Site", "city": "El Paso", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Research Site", "city": "Fort Worth", "state": "Texas", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Spring", "state": "Texas", "country": "United States", "geoPoint": {"lat": 30.07994, "lon": -95.41716}}, {"facility": "Research Site", "city": "Aguas Buenas", "country": "Puerto Rico", "geoPoint": {"lat": 18.2569, "lon": -66.10294}}, {"facility": "Research Site", "city": "Caquas", "country": "Puerto Rico"}, {"facility": "Research Site", "city": "Cidra", "country": "Puerto Rico", "geoPoint": {"lat": 18.17579, "lon": -66.16128}}, {"facility": "Research Site", "city": "Levittown", "country": "Puerto Rico", "geoPoint": {"lat": 18.44995, "lon": -66.18156}}, {"facility": "Research Site", "city": "Ponce", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Research Site", "city": "SanJuan", "country": "Puerto Rico"}, {"facility": "Research Site", "city": "Trujillo Alto", "country": "Puerto Rico", "geoPoint": {"lat": 18.35467, "lon": -66.00739}}]}, "referencesModule": {"references": [{"pmid": "22329608", "type": "DERIVED", "citation": "Murphy KR, Uryniak T, Martin UJ, Zangrilli J. The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma. Drugs R D. 2012 Mar 1;12(1):9-14. doi: 10.2165/11630600-000000000-00000. Erratum In: Drugs R D. 2012 Mar 1;12(1):15."}, {"pmid": "21875546", "type": "DERIVED", "citation": "Zangrilli J, Mansfield LE, Uryniak T, O'Brien CD. Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial. Ann Allergy Asthma Immunol. 2011 Sep;107(3):258-65.e2. doi: 10.1016/j.anai.2011.05.024. Epub 2011 Jul 14."}], "seeAlsoLinks": [{"label": "Related Info", "url": "http://www.asthmaclinicaltrials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Male or female, Hispanic (self-reported), \u226512 years", "recruitmentDetails": "39 centres in United States enrolled 558 patients with asthma into this study. 308 patients were excluded: 279 for incorrect enrollment/eligibility criteria not fulfilled, 14 for voluntary discontinuations, 2 for development of study specific discontinuation criteria, 2 for adverse events, 10 were lost to follow-up", "groups": [{"id": "FG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "FG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Randomized patients", "numSubjects": "127"}, {"groupId": "FG001", "comment": "Randomized patients", "numSubjects": "123"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Randomized patients", "numSubjects": "109"}, {"groupId": "FG001", "comment": "Randomized patients", "numSubjects": "102"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "21"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Study specific discontinuation criteria", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Multiple reasons", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "BG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "127"}, {"groupId": "BG001", "value": "123"}, {"groupId": "BG002", "value": "250"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "16.6", "spread": "39.8"}, {"groupId": "BG001", "value": "14.9", "spread": "37.0"}, {"groupId": "BG002", "value": "15.6", "spread": "38.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "80"}, {"groupId": "BG002", "value": "164"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "86"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Morning Peak Expiratory Flow (AM PEF)", "description": "Change from baseline (average of daily records over the 14 days of run-in) to the average of daily records over the treatment period of 12 weeks, with baseline value as covariate.", "populationDescription": "Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters/minutes", "timeFrame": "Baseline (run-in) and throughout 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25.40", "spread": "6.0", "lowerLimit": "+/-6.0"}, {"groupId": "OG001", "value": "19.90", "spread": "6.5", "lowerLimit": "+/-6.5"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Pre-defined Asthma Events", "description": "Asthma Events, defined as any of: decrease in lung function (FEV1 or AM PEF), use of rescue medication over maximum allowed per day, night awakening requiring use of rescue medication, exacerbation of asthma requiring medical assistance, use of not allowed asthma medication", "populationDescription": "Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25.20"}, {"groupId": "OG001", "value": "31.70"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With \"Withdrawals Due to Pre-defined Asthma Events\"", "description": "Percentage of participants with \"Withdrawals Due to Pre-defined Asthma Events\" as recorded in CRF. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "populationDescription": "Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "92"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.10"}, {"groupId": "OG001", "value": "6.50"}]}]}]}, {"type": "SECONDARY", "title": "Changes Pre-dose Forced Expiratory Volume in 1 Second (FEV1)", "description": "Changes in pre-dose FEV1 from baseline to the average value over the treatment period, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "populationDescription": "Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters", "timeFrame": "Baseline, 2, 6 and 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "122"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "0.03", "lowerLimit": "+/-0.03"}, {"groupId": "OG001", "value": "0.11", "spread": "0.03", "lowerLimit": "+/-0.03"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in a Evening Peak Expiratory Flow (PM PEF)", "description": "Change from baseline (average of daily records over the 14 days of run-in) to the average of daily records over the treatment period of 12 weeks with baseline as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "populationDescription": "Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liters/minutes", "timeFrame": "Baseline (run-in) and throughout 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "124"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.60", "spread": "6.2", "lowerLimit": "+/-6.2"}, {"groupId": "OG001", "value": "15.80", "spread": "6.7", "lowerLimit": "+/-6.7"}]}]}]}, {"type": "SECONDARY", "title": "Change in Nighttime Asthma Symptom Score From Baseline Through 12 Weeks", "description": "Change from baseline in average of daily scores for nighttime asthma over 12 weeks of treatment, with baseline value as covariate.\n\nDaily scale:\n\n* 0 = No symptoms\n* 1 = Mild symptoms\n* 2 = Moderate symptoms\n* 3 = Severe symptoms", "populationDescription": "Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline (run-in) and throughout 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.40", "spread": "0.01", "lowerLimit": "+/-0.01"}, {"groupId": "OG001", "value": "-0.30", "spread": "0.01", "lowerLimit": "+/-0.01"}]}]}]}, {"type": "SECONDARY", "title": "Change in Daytime Asthma Symptom Score From Baseline Through 12 Weeks", "description": "Change from baseline in average of daily scores for daytime asthma over 12 weeks of treatment, with baseline value as covariate.\n\nDaily scale:\n\n* 0 = No symptoms\n* 1 = Mild symptoms\n* 2 = Moderate symptoms\n* 3 = Severe symptoms", "populationDescription": "Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "Baseline (run-in) and throughout 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.40", "spread": "0.01", "lowerLimit": "+/-0.01"}, {"groupId": "OG001", "value": "-0.30", "spread": "0.01", "lowerLimit": "+/-0.01"}]}]}]}, {"type": "SECONDARY", "title": "Change in Asthma Related Awakenings Free Nights, From Baseline Through 12 Weeks", "description": "Change from baseline in percentage of nights with awakenings due to asthma over 12 weeks of treatment, with baseline value as covariate.", "populationDescription": "Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of nights", "timeFrame": "Baseline (run-in) and throughout 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.40", "spread": "1.7", "lowerLimit": "+/-1.7"}, {"groupId": "OG001", "value": "5.50", "spread": "1.9", "lowerLimit": "+/-1.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Rescue Medication Use Over 12 Weeks of Treatment", "description": "Change from baseline in rescue medication use over 12 weeks of treatment with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "populationDescription": "Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "puffs/day", "timeFrame": "Baseline (run-in) and throughout 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.80", "spread": "0.20", "lowerLimit": "+/-0.20"}, {"groupId": "OG001", "value": "-0.60", "spread": "0.20", "lowerLimit": "+/-0.20"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Rescue-free Days Over 12 Weeks of Treatment", "description": "Change from baseline in percentage of rescue-free days over 12 weeks of treatment, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "populationDescription": "Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of days", "timeFrame": "Baseline (run-in) and throughout 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19.70", "spread": "3.30", "lowerLimit": "+/-3.30"}, {"groupId": "OG001", "value": "17.70", "spread": "3.50", "lowerLimit": "+/-3.50"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Symptom-free Days Over 12 Weeks of Treatment", "description": "Change from baseline in percentage of symptom-free days over 12 weeks of treatment, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "populationDescription": "Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage of days", "timeFrame": "Baseline (run-in) and throughout 12 weeks", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "24.40", "spread": "3.30", "lowerLimit": "+/-3.30"}, {"groupId": "OG001", "value": "21.00", "spread": "3.50", "lowerLimit": "+/-3.50"}]}]}]}, {"type": "SECONDARY", "title": "Subject Global Assessment", "description": "The assessment was made using a 5-point Likert scale with 1=much better, 2=somewhat better, 3=comparable, 4=somewhat worse, and 5=much worse transformed to a binary variable with points 1 and 2 combined as \"Yes\" and points 3, 4, 5 as \"No\". Percent of Participants that gave positive responses.", "populationDescription": "Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percent of Participants", "timeFrame": "Baseline and week 12", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "88.70"}, {"groupId": "OG001", "value": "86.30"}]}]}]}, {"type": "SECONDARY", "title": "Physician Global Assessment", "description": "The assessment was made using a 5-point scale with 1=much better, 2=somewhat better, 3=comparable, 4=somewhat worse, and 5=much worse transformed to a binary variable with points 1and 2 combined as \"Yes\" and points 3, 4, 5 as \"No\". Percent of Participants that gave positive responses.", "populationDescription": "Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Perscentage of Participants", "timeFrame": "Baseline and week 12", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "125"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "92.00"}, {"groupId": "OG001", "value": "84.60"}]}]}]}, {"type": "SECONDARY", "title": "Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Control Relief Index", "description": "Mean scores (6-points scale, where 1-means the most positive opinion and 6-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0\u00b1100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.", "populationDescription": "Only subjects 18 years and older, who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "87.20", "spread": "1.97", "lowerLimit": "+/-1.97"}, {"groupId": "OG001", "value": "82.50", "spread": "2.08", "lowerLimit": "+/-2.08"}]}]}]}, {"type": "SECONDARY", "title": "Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Overall Perception of Medication", "description": "Mean scores (6 or 5-points scale, where 1-means the most positive opinion and 5/6-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0\u00b1100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.", "populationDescription": "Only subjects 18 years and older, who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2 actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "budesonide HFA pMDI 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "90.67", "spread": "1.79"}, {"groupId": "OG001", "value": "86.66", "spread": "1.89"}]}]}]}, {"type": "SECONDARY", "title": "Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Comparison With Other Medications", "description": "Mean scores (5-points scale, where 1-means the most positive opinion and 5-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0\u00b1100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.", "populationDescription": "Only subjects 18 years and older, who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Units on a scale", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2 actuations twice daily"}, {"id": "OG001", "title": "Budesonide", "description": "budesonide HFA pMDI 160 \u03bcg x 2 actuations twice daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "88.45", "spread": "2.34"}, {"groupId": "OG001", "value": "80.60", "spread": "2.47"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "eventGroups": [{"id": "EG000", "title": "Symbicort", "description": "SYMBICORT\u00ae pMDI 160/4.5 \u03bcg x 2 actuations twice daily", "seriousNumAffected": 4, "seriousNumAtRisk": 127, "otherNumAffected": 69, "otherNumAtRisk": 127}, {"id": "EG001", "title": "Budesonide", "description": "budesonide HFA pMDI 160 \u03bcg x 2 actuations twice daily", "seriousNumAffected": 0, "seriousNumAtRisk": 123, "otherNumAffected": 48, "otherNumAtRisk": 123}], "seriousEvents": [{"term": "Gastrointestinal Hemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 10.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Status Asthmaticus", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}], "otherEvents": [{"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 123}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 123}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 123}]}, {"term": "Dysmenorrhoea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Ear Pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 123}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Nasal Congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Pharyngitis Streptococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Pharyngolaryngeal Pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 123}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 123}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 123}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 123}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 123}]}, {"term": "Viral Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 127}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 123}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}